IW 364

May 3, 2026 Viktor Zarev 0 min read
  1. Trump dumps Means, nominates radiologist as surgeon general. 
  2. Physician groups want better enforcement of “no surprises” law.
  3. FDA tells Amgen to pull vasculitis drug off market.
  4. FDA grants early access to drug for pancreatic cancer.
  5. DOJ strike force targets healthcare fraud in western U.S. states.
  6. Surprising study with OpenAI’s LLM prompts physician introspection. 
  7. Visa delays threaten foreign doctor placements in rural areas. 
  8. Feds implement rule capping loans for graduate-level providers.
  9. Cigna bails on ACA exchanges, “explores alternatives” for EviCore.
  10. Is the “psychedelic revolution”leaving minorities behind?
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Pharmaceuticals May 7, 2026

Aficamten, ACACIA-HCM, and the Road to the First nHCM Drug May 7, 2026

The question of how to treat non-obstructive hypertrophic cardiomyopathy has long perplexed researchers and pharmaceutical developers alike, but topline results from Cytokinetics’ Phase 3 ACACIA-HCM trial suggest MYQORZO (aficamten) could be the answer.

Cardiovascular Disease May 4, 2026

The True Cause of Sudden Cardiac Death May 4, 2026

It’s not often that a pair of studies completely challenges our assumptions in cardiology, but new data presented at HRS 2026 suggests myocardial infarction might not be […]

Cardiology April 30, 2026

Cardiac Wire’s Top Six of HRS 2026 April 30, 2026

The Heart Rhythm Society's Annual Meeting for 2026 electrified Chicago with talks of the latest EP tech, rhythm management debates, and insights into where remote patient monitoring is headed. Here are Cardiac Wire’s top-six takeaways from electrophysiology’s biggest weekend of the year.